Antibody Drug Conjugates Contract Manufacturing Market Projected To Reach USD 18.4 Billion By 2028

 San Francisco, 27 Jan 2022: The Report Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer), By Linker (Cleavable Linker, Non-cleavable Linker), By Region, And Segment Forecasts, 2021 - 2028

The global antibody drug conjugates contract manufacturing market size is anticipated to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.3% from 2021 to 2028. The factors driving market expansion is complex nature of Antibody Drug Conjugates (ADCs), increasing demand for manufacturing capacity as well as increasing number of research on antibody therapies.

Around 70.0% of ADC projects are outsourced to contract development and manufacturing organisations. As ADCs are complex molecules, they require clean room biologic and high containment cytotoxic facilities for safe handling. Hence, there are real opportunities for companies that can provide specialised, innovative chemistries that require skilled workers.

ADCs are currently a niche market, with few CMOs offering all of the drug's components, resulting in a complex supply chain. Besides, with seven commercially authorised ADC on the market and roughly 90 projects in clinical trials, it is essential to reduce the complicated supply chain in order to increase production efficiency. For the success of the trial, a transparent and integrated supply chain is essential.

The coronavirus pandemic has assessed a typically optimistic and deliberate approach to monoclonal antibody development and disrupting supply chains not only for those antibodies deemed most promising a year ago, but also for others antibody drug conjugate that have been thrust into the spotlight as potential COVID-19 treatments.The COVID-19 pandemic has generated a strong and quick reaction from scientists working in government, and industries to create medicines and vaccines. As a result of the increasing demand for effective COVID-19 treatment medicines, global production of vaccines, antibody drug conjugates, and other pharmaceuticals is projected to expand.

Access Research Report of Antibody Drug Conjugates Contract Manufacturing Market @ https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-contract-manufacturing-market-report

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights

• By condition, the myeloma segment dominated the market and accounted for the largest revenue share of 49.4% in 2020. This is largely due to the fact that antibody-drug conjugates are a novel form of immunotherapy presently being researched and evaluated in the treatment of myeloma
• Based on the linker, the cleavable linker segment accounted for a maximum share of 56.5% in 2020. Extensive use of cleavable linker technology in ADC and a greater number of cleavable linker-based authorised products are the factor responsible for the growth
• Asia Pacific dominated themarket in 2020 due to the robust improvements in research and development activities, emerging markets, and competition in the pharmaceutical CMO sector
• In 2018, nearly 202 ADCs have entered the clinical trials and there were about 23 novel ADCs in the last 12 months increasing at a rate of 30.0%

List of Key Players of the Antibody Drug Conjugates Contract Manufacturing Market

• Cambrex
• ReciPharm
• ThermoFisher
• Pantheon
• Corden Pharma
• Samsung Biologics
• Lonza
• Catalent
• Siegfried
• Piramal Pharma Solutions
• Boehringer Ingelheim

Access Press Release of Antibody Drug Conjugates Contract Manufacturing Market @ https://www.grandviewresearch.com/press-release/global-antibody-drug-conjugates-contract-manufacturing-market